New regimens for reducing the duration of treatment of drug-susceptible pulmonary tuberculosis

Drug Development Research

Volumn 72, Issue 6, 2011, Pages 501-508

  Conde, Marcus B ^a   Lapa E Silva, José R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

clinical trial; drugs; fluoroquinolones; rifapentine; treatment; tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; DELAMANID; LL 3858; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

HEALTH CARE COST; HUMAN; LUNG TUBERCULOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PUBLIC HEALTH PROBLEM; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT REFUSAL;

EID: 80052995319     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20456     Document Type: Review

References (48)

1. Anon. Avelox (moxifloxacin hydrochloride) package insert. Bayer, December 2005.
2. Anon. Priftin (rifapentine) package insert. Aventis, February 2003.
3. Bemer-Melchior P, Bryskier A, Drugeon HB., 2000. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 46: 571-576.
4. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, et al.; Tuberculosis Trials Consortium. 2002. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360: 528-534.
5. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, et al. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174: 331-338. (Pubitemid 44156613)
6. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM., 2005. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 352: 1646-1654. (Pubitemid 40530231)
7. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA., 1990. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 112: 407-415.
8. Conde MB, Efron A, Loredo C, Souza GRM, Cezar MC, Graça NP, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE., 2009. Moxifloxacin in the initial therapy of tuberculosis: a randomized, phase 2 trial. Lancet 373: 1183-1189.
9. Daniel N, Lounis N, Ji B, O'Brien RJ, Vernon A, Geiter LJ, Szpytma M, Truffot-Pernot C, Hejblum G, Grosset J,. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. 2000. Long-term effectiveness with 6- and 8-month treatment regimens. Am J Respir Crit Care Med 161: 1572-1577.
10. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, Donald PR, van Niekerk C, Whitney K, Rouse DJ, et al. 2010. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 54: 3402-3407.
11. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, et al.; Tuberculosis Trials Consortium. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 180: 273-280.
12. el-Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, Olibrice M, Medard F, Chirgwin KD, Mildvan D, et al. 1998. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 26: 1148-1158. (Pubitemid 28215480)
13. Frothingham R., 2001. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 21: 1468-1472. (Pubitemid 33117251)
14. Gillespie SH, Billington O., 1999. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 44: 393-395. (Pubitemid 29425693)
15. Ginsberg AM., 2008. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 29: 552-559.
16. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH., 2003. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 168: 1342-1345. (Pubitemid 37487329)
17. Iannini PB, Kubin R, Reiter C, Tillotson G., 2001, Reassuring safety profile of moxifloxacin. Clin Infect Dis 32: 1112-1114.
18. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J., 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 42: 2066-2069. (Pubitemid 28363094)
19. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, et al. 2006. Early and extended early bactericidal activity of levofloxacin, gatifloxacin, and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 10: 605-612. (Pubitemid 43845020)
20. Kennedy N, Fox R, Uiso L, Ngowi FI, Gillespie SH., 1993a. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. J Antimicrob Chemother 32: 897-902. (Pubitemid 24026591)
21. Kennedy N, Fox R, Kisyombe GM, Saruni AO, Uiso LO, Ramsay AR, Ngowi FI, Gillespie SH., 1993b. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 148: 1547-1551. (Pubitemid 24002485)
22. Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisyombe GM, Ngowi FI, Ramsay AR, Saruni AO, Sam N, et al. 1996. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 22: 827-833. (Pubitemid 26255603)
23. Lenaerts AJ, Gruppo V, Marietta KS., 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49: 2294-2301. (Pubitemid 40734457)
24. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J., 2001 Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 45: 3482-3486. (Pubitemid 33107866)
25. Manjunatha UH, Boshoff H, Dowd CS., 2006. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 103: 431-436. (Pubitemid 43122418)
26. McDonald RJ, Memon AM, Reichman LB., 1982. Successful supervised ambulatory management of tuberculosis treatment failures. Ann Intern Med 96: 297-302. (Pubitemid 12187505)
27. Mitchison DA., 2006. Clinical development of anti-tuberculosis drugs. J Antimicrob Chemother 58: 494-495. (Pubitemid 44288110)
28. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR., 1999. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 43: 85-89. (Pubitemid 29069204)
29. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH., 2004a. Moxifloxacin- containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170: 1131-1134. (Pubitemid 39488628)
30. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH., 2004b. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169: 421-426. (Pubitemid 38134824)
31. Nuermberger E, Tyagi S, Tasneen R., 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52: 1522-1524. (Pubitemid 351522025)
32. O'Brien RJ, Nunn PP., 2001. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am J Respir Crit Care Med 163: 1055-1058. (Pubitemid 32378435)
33. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM., 2006. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354: 1352-1361.
34. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H., 2004. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 48: 780-782. (Pubitemid 38280324)
35. Rodriguez JC, Ruiz M, Climent A, Royo G., 2001. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 17: 229-231. (Pubitemid 32229902)
36. Saigal S, Agarwal SR, Nandeesh ND, Sarin SK., 2001. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol 16: 1028-1032. (Pubitemid 32947146)
37. Silva AD, Almeida MV, Souza MVN, Couri MRC., 2003. Biological activity and synthetic methodologies for the preparation of fluoroquinolones. A class of potent antibacterial agents. Curr Med Chem 10: 21-39. (Pubitemid 36131647)
38. Singla R, Gupta S, Gupta R, Arora VK., 2001. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results. Int J Tuberc Lung Dis 5: 559-563. (Pubitemid 32587287)
39. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, Tam CM, Kam KM, Lam CW, Sole KM, Mitchison DA., 2000. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 45: 859-870. (Pubitemid 30348958)
40. Stover CK, Warrener P, VanDevanter DR., 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966. (Pubitemid 30435054)
41. Tortoli E, Dionisio D, Fabbri C., 2004. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains. J Chemother 16: 334-336. (Pubitemid 39049881)
42. Tuberculosis Research Centre. 2002. Shortening short course chemotherapy: a randomized clinical trial for treatment of smear-positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc 49: 27-38.
43. Tyagi S, Nuermberger E, Yoshimatsu T., 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49: 2289-2293. (Pubitemid 40734456)
44. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S., 2003. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 15: 66-70. (Pubitemid 36355891)
45. WHO. 2006. Global tuberculosis control-surveillance, planning, financing. WHO Report 2006. WHO/HTM/TB/2006.362. [Available at, accessed on August 16, 2006.]
46. WHO. 2009. Treatment of tuberculosis: guidelines. 4th ed. WHO/HTM/TB/2009.420.
47. Yew WW, Kwan SYL, Ma WK, Aung MK, Chau PY., 1990. In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 26: 227-236. (Pubitemid 20266019)
48. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, Lee J., 2000. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117: 744-751. (Pubitemid 30152215)